--- title: "Weekly Recap | Hims & Hers Health -3.92%, FTC suit and class actions in focus" type: "News" locale: "en" url: "https://longbridge.com/en/news/298098787.md" description: "Hims & Hers Health (HIMS) fell 3.92% this week to close at $27.71, while the S&P 500 edged up 0.09%, leaving the stock about 4.01 percentage points behind. The week shaped up as a failed push higher: Monday opened near $28.67 and closed up at $29.58, Tuesday tagged the week’s high of $29.87 before fading, and the final three sessions drifted lower, with Thursday breaking below $28 on heavier volume and Friday hitting a low of $27.38 before settling at $27.71. The weekly range of 8." datetime: "2026-09-05T07:07:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298098787.md) - [en](https://longbridge.com/en/news/298098787.md) - [zh-HK](https://longbridge.com/zh-HK/news/298098787.md) generator: "portal-rs" --- # Weekly Recap | Hims & Hers Health -3.92%, FTC suit and class actions in focus ## The Week Hims & Hers Health (HIMS) fell 3.92% this week to close at $27.71, while the S&P 500 edged up 0.09%, leaving the stock about 4.01 percentage points behind. The week shaped up as a failed push higher: Monday opened near $28.67 and closed up at $29.58, Tuesday tagged the week’s high of $29.87 before fading, and the final three sessions drifted lower, with Thursday breaking below $28 on heavier volume and Friday hitting a low of $27.38 before settling at $27.71. The weekly range of 8.69% kept the stock inside the broad band between the July 30 low of $24.24 and the July 6 high of $39.05. ## Key Events The clearest company-specific line was international expansion: Hims & Hers announced on Monday its entry into Australia, marking its first move into Asia-Pacific, with GLP-1 weight-loss drugs and men’s health treatments offered there. On the regulatory and legal side, Friday brought reports that the FTC had sued over mislabelled GLP-1 medications, followed by several law firms seeking shareholders to lead securities class actions tied to the disclosure-driven share decline. Also on Friday, Chief Legal Officer Soleil Boughton disclosed the sale of 3,458 shares for roughly $98,000. These two threads sit close together in time and framed the week’s narrative, though the news and price action read as correlated rather than causal. ## Analyst Ratings As of the 3 September aggregate, 16 institutions cover Hims & Hers Health: 1 buy, 2 overweight, 11 hold, 1 underweight, and 1 with no opinion. The consensus rating is hold, with a consensus target of $31.23, about 12.71% above the $27.71 spot. Target prices range from $23 to $42, a wide spread that points to real disagreement on the outlook. Within the healthcare services industry, the stock ranks 8th out of 53 names on ratings, in the upper-middle tier. ## The Week Ahead The FTC case and the securities class-action efforts will extend into next week: whether more law firms solicit shareholders and whether management responds on labelling are the key company-level questions. On the macro calendar, Tuesday brings the NFIB Small Business Optimism Index, and Thursday is dense with initial jobless claims, final-demand PPI, existing home sales, and wholesale sales. PPI forecasts sit above the prior readings; a hotter print could feed a repricing of rate expectations and amplify swings in high-valuation growth names. ## In Short This week’s pullback coincided with a lawsuit disclosure and a lukewarm sell-side stance: the consensus rating is hold, 11 of 16 institutions are at hold, and only 3 are buy or overweight, yet the consensus target still sits about 12.71% above spot with a very wide target range. The stock is currently loss-making, at a negative 45.52x P/E and roughly 19.95x book, so growth expectations remain priced fairly high. Latest-session money flows show large-lot sellers against small- and mid-lot buyers, a mixed signal. What comes next hinges on whether the FTC action widens, how the Australia and GLP-1 rollout progresses, and how a richly valued stock absorbs macro data risk. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md) - [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md) ## Related News & Research - [FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades](https://longbridge.com/en/news/301732477.md) - [Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately](https://longbridge.com/en/news/301846716.md) - [Hims & Hers Health Expands Testosterone Care With Injectable And Oral TRT](https://longbridge.com/en/news/302564954.md) - [HealFast Expands Patient-First Mission into Weight Loss and Metabolic Health Support with Telehealth Launch](https://longbridge.com/en/news/302022773.md) - [Hims & Hers Health launches online weight management service for men in Germany](https://longbridge.com/en/news/302427301.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**